
U.S. Grants Priority Review to Ifinatamab Deruxtecan for Previously Treated ES-SCLC After Platinum Therapy
U.S. Grants Priority Review to Ifinatamab Deruxtecan for Previously Treated ES-SCLC Patients After Platinum Therapy Daiichi Sankyo and Merck & Co. have reached an important regulatory milestone with the U.S. Food and Drug Administration accepting their Biologics License Application (BLA)…












